Antibody neutralization of the extracellular enveloped form of vaccinia virus.
The extracellular enveloped form (EEV) of vaccinia virus (VV) is important for the long-range dissemination of the virus inside the host. Early work suggested that both IMV and EEV infectivity could be inhibited by antibodies, although two other studies reported that EEV was resistant to neutralization. Here, we readdressed this question, using four VV-immune antisera and their purified IgG, and showed that EEV infectivity can be inhibited by antibody produced from a live infection in plaque-reduction assays, although EEV is more resistant to neutralization by convalescent antibodies than is IMV. In parallel, indirect immunofluorescent staining and confocal microscopy showed that antibody aggregated EEV and prevented it from binding to cells. Using the IgG and Fab fragments prepared from this antiserum, we tested whether EEV made by VV mutants lacking genes A33R, A34R, A36R, A56R, B5R, F12L, or F13L can be inhibited in plaque-reduction assays. Although vDeltaB5R was slightly more resistant than other mutants, none of these mutants escaped neutralization completely, suggesting that multiple virus proteins are involved in the inhibition. Using an antibody specific to B5R protein and B5R mutants with consecutive short consensus repeat (SCR) domains deleted, the neutralization epitopes on B5R were mapped to within the SCR domain 1.